The metabolic syndrome (MetS) is associated with a rise in blood pressure (BP) however the 30 mechanisms underlying this association are not known. Nivar and colleagues utilize a number 31 of innovative approaches to evaluate the role of the epithelial sodium channel (ENaC) of the 32 renal collecting duct in the sodium retention and hypertension associated with MetS. C57Bl/6 33 male, mice fed a high-fat diet for 12 weeks developed several features of MetS including: 34 hyperinsulinemia, hypercholesterolemia, obesity, and elevated BP. They also showed salt-35 sensitive hypertension and sodium retention in the early time course of switch from normal to a 36 high-NaCl diet. Nonetheless, they found no evidence of over-activity of ENaC, using both 37 perfused tubules and in vivo (sensitivity to benzamil) approaches. The authors concluded 38 alternative, perhaps upstream sites of sodium retention. The studies are important in that they 39 highlight the complexity of metabolic syndrome, and shed some new light in a controversial 40 area. They do support renal sodium retention may be at the core, and elucidation of these 41 upstream pathways is in need of additional study. 42
Metabolic syndrome (MetS) is associated with elevations in blood pressure (BP); 44 however, the relationships between key variables remain murky. First of all defining and 45 modeling MetS is difficult at best. In its simplest terms, MetS may be described as a "disease 46 state" or set of conditions resulting from an excess of stored and/or circulating energy. 47 Associated conditions include: visceral adiposity, hyperinsulinemia (due to insulin resistance of 48 major metabolic tissues), dyslipidemia, and hypertension. A current estimate by the American 49
Heart Association is that 1 in 3 U.S. adults has MetS (1). How (or whether) the various 50 metabolic features of MetS lead to hypertension is an area of intense scrutiny, not only due to 51 the large numbers of persons afflicted, but also due to the high life-time cardiovascular risk of 52
Utilizing a number of elegant approaches, Nizar et al. (8) recently examined the role of 54 the epithelial sodium channel (ENaC) in the sodium retention and hypertension associated with 55
MetS. The investigators initially screened two different mouse models of MetS, i.e., chronically 56 high-fat-fed and high-fructose-fed male C57Bl/6 mice. After several weeks of treatment, only 57 the mice on the high-fat regimen (60% high-fat diet for 12 weeks) developed symptoms of MetS 58 including weight gain, hyperinsulinemia, hypercholesterolemia, glucose intolerance, and 59 modestly elevated BP (~3 mm Hg, by radiotelemetry). Therefore, they used this model to 60 perform additional studies. One stumbling block in modeling hypertension associated with MetS 61 is that many rodent models do not develop significant hypertension when obese. The obese 62
Zucker rat, e.g., is markedly obese, insulin resistance, and hypertriglyceridemic; however, they 63
show only a modest elevations in BP except when infused with aldosterone (9). Fructose-fed 64 rats develop insulin resistance, hypertriglyceridemia, and hypertension, but are not necessarily 65 obese. Moreover, the strain of mice selected in the Nizar study (8), i.e., C57Bl/6, have 66 inconsistent changes in BP with high-fat diets (5). Nonetheless, in agreement, not all human 67 subjects with MetS have hypertension.
when switched from a normal to a high-NaCl diet, and this impairment coincided with a 70 significantly greater salt-sensitive rise in BP. It is assumed they chose to focus on ENaC 71 because it is a prime candidate with regard to linking the metabolic factors associated with MetS 72 to hypertension (Figure 1 
30 mm Hg rise in systolic BP (7). Moreover, there are numerous circulating, paracrine, and 76 basic physiological conditions, i.e., acid-base homeostasis, which may be altered in MetS, and 77 have been found to increase ENaC activity (4). These include, but are not limited to, angiotensin 78 II, aldosterone, superoxide, and insulin. ENaC has been demonstrated to be activated by 79 insulin; however, ex vivo doses needed to show activation (1-100 nM) are often much higher 80 than the physiological range for insulin (~0.02-2 nM or 14-290 μIU/ml). insulin. In contrast, we found that administration of insulin to achieve a circulating level of no 83 greater than 0.3 nM, resulted in anti-natriuresis. This anti-natriuresis was partially attenuated by 84 benzamil (10) or in collecting duct principal cell insulin receptor knockout mice (6). Acute insulin 85 administration was also associated with greater ENaC localization of the apical membrane of 86 the collecting duct (10). Additional studies will be needed to clarify insulin's actions on ENaC. 87 Nevertheless, in the Nizar et al. (8) study, ENaC activity was found not to be different 88 between high-fat fed mice and controls, as measured in vivo by benzamil (ENaC antagonist) 89 sensitivity and using isolated perfused cortical collecting ducts. Antagonizing ENaC with 90 benzamil in a more chronic fashion also did not affect the elevation in BP. Moreover, the 91 investigators also found no differences in aldosterone excretion between the groups. Therefore, 92 they concluded that MetS, at least in this particular mouse model, was associated with sodiumretention and an elevation in BP independent from elevated ENaC, and likely due to activation 94 of more upstream sodium-retentive mechanisms. 95
This group of investigators did not set out to test the role of elevated insulin or any other 96 specific metabolic factor in their analyses. More than likely, they were aiming to develop a 97 meaningful model of human MetS, with all its complexity. The mice were hyperinsulinemic and 98 insulin has been demonstrated to be anti-natriuretic at a number of sites along the renal tubule 99 in addition to the collecting duct, including, the proximal tubule, the thick ascending limb, and 100 the distal convoluted tubule. Therefore there are a number of potential alternative sodium-101 retentive pathways that could be activated by insulin or another factor. 102
Insulin may explain sodium retention, but its direct effects on BP are less certain. There 103 are other systems that manage BP as their principal action, e.g., the renin-angiotensin-104 aldosterone, the autonomic nervous, and the sympathetic nervous systems, as well as local 105 mediators, e.g., NO and endothelin (2). Morever, insulin has been demonstrated to have two 106 distinct opposing actions on BP, i.e., sodium retention and NO release. The balance of these 107 countering actions may underlie some of the inconsistencies observed. Finally, the high-fat fed 108 mice in the current study were found not only to be hyperinsulinemic, but also insulin resistant 109 (using the HOMA-IR assay). Insulin receptor resistance can diminish but also alter intracellular 110 signaling, so that the end-point ramifications are markedly different. Whether or not the kidney 111 insulin receptor becomes resistant in MetS is uncertain. 112
Thus, it is likely that a combination of factors or a distinct "metabolic milieu" is required in 113 order for MetS to result in hypertension. In addition to insulin, important factors likely include, 114 the RAAS, inflammatory mediators, free radicals, and adipokines. The authors provide keen 115 evidence of a renal role in this hypertension with sodium-retention distinct from ENaC as a 116 characteristic feature in C57Bl/6 mice fed a high-fat diet. 117 118 119 120 
